Partners

Galician Innovation Agency is a regional public agency, assigned to the Ministry of Economy, Entrepreneurship and Industry but with its own legal personality, which aims to promote and structure innovation policies in Galician public administrations, and the support and promotion of the growth and competitiveness of Galician companies, through the implementation of efficient innovation strategies and programs.

Its main objectives are to promote and develop activities aimed at encouraging, improving, guiding, and disseminating the study and scientific research of cancer, in any of its manifestations and aspects.

It promotes research that responds to today’s great challenges such as the search for effective prevention and early detection strategies, the improvement of diagnostic processes and the development of life-saving treatments.

As part of its activity, the Foundation has allocated more than 80 million euros to cancer research, and has closed 200 collaboration agreements with different research groups, currently with more than 340 projects in the field of cancer that they can continue to be developed and valued through their scientific incubation in more advanced stages.

Kærtor Foundation, a pioneer in early drug development in public/private collaboration
The Kærtor Foundation is a private non-profit foundation, listed in the Register of Foundations of Galician Interest of the Xunta de Galicia, under the protectorate of the Ministry of Economy and Industry. Its objective is to provide expert knowledge in drug discovery that helps transform, guide and accelerate research projects towards new therapies for unmet medical needs. In addition, it serves as an instrument to connect basic research in drug discovery with the pharmaceutical industry in a reverse transference framework in open innovation.

The Kærtor Foundation has a team with more than 20 years of experience and 15 new drugs in clinical trials in public/private partnerships. It has developed a highly efficient methodology in drug discovery, reducing time and costs. This methodology has recently been validated in the I2D2 program (Incubation Innovation in Drug Discovery), carried out by the Galician Innovation Agency, the Janssen company and the Kærtor Foundation, that launched the first incubator of disruptive science programs applied to transformational drug discovery in Spain.

Janssen, a multinational pharmaceutical research company belonging to the Johnson & Johnson group, one of the most diversified and consolidated companies in the healthcare sector, which stands out for its great capacity for innovation. As part of R&D activity, more than 400,000 new molecular entities have been discovered at Janssen, 80 of which have become original drugs. Janssen researches and develops numerous drugs in Spain in advanced therapeutic areas such as immunology, oncology, neuroscience, cardiovascular and metabolism.

Eli Lilly is one of the ten leading pharmaceutical companies in the world. With 144 years of existence, approximately 33,000 employees and headquartered in Indianapolis, it is a global corporation based on research and oriented towards innovation. Its objective is to develop the best drugs in its class and the first series of its therapeutic groups, applying the latest research in its laboratories and using the most advanced technological tools, as well as collaborating with renowned scientific organizations.

Lilly is present on five continents and has Research and Development facilities in eight countries, among which the Alcobendas Medical Chemistry Research Centre stands out, the company’s most important in Europe.

Lilly is committed to fighting cancer. For more than 50 years, he has been contributing to the history of oncology by providing innovative medicines that improve the lives of patients and their loved ones.

Our goal is to end cancer. While we get to that moment, our efforts are directed from the research and development of new drugs, to obtaining and providing better treatments that allow patients to live longer and with a better quality of life.
As a result of the advancement of science, we are currently working to improve the lives of people affected by breast cancer, stomach cancer, and lung cancer, among others. These tumours are also among the most frequently diagnosed in 2018.
In addition, it should be noted that between 30 and 50% of cancer cases can be prevented. Knowing the risk factors and favouring early detection and prevention will help reduce cancer cases in our society. (ref. Cancer figures in Spain 2020. SEOM)

Lilly’s promise is to provide treatments that improve the quality of life for patients. This highlights the importance that the company places on its capacity for discovery and innovation.